Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nobel Signs Licensing Deal With SRI For Endometriosis Drug

This article was originally published in PharmAsia News

Executive Summary

Nobel Pharma Japan has entered into a license agreement with SRI International regarding the domestic clinical trials and development of SRI’s endometriosis drug candidate SR16234.

You may also be interested in...



FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions

Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

News We’re Watching: Biden Moves To Strengthen Supply Chain; More Medtech-Related Prosecutions; $5.5M Sepsis Grant For Siemens

This week, the Biden administration announced a new council on supply chain resilience that includes health care goals; an apparent enforcement surge against device fraud continued; Siemens won a $5.5m grant to develop a better sepsis test; and the FDA proposed new classifications for wound care products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC088145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel